These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 2782914)
1. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery]. Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914 [TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer]. Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882 [TBL] [Abstract][Full Text] [Related]
3. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients]. Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168 [TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma. Iemura K; Moriya Y Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479 [TBL] [Abstract][Full Text] [Related]
5. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491 [TBL] [Abstract][Full Text] [Related]
6. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer]. Anzai K; Kurihara M; Izumi T Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836 [TBL] [Abstract][Full Text] [Related]
7. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma. Forslund A; Engarås B; Lönnroth C; Lundholm K Int J Oncol; 2002 May; 20(5):1013-8. PubMed ID: 11956598 [TBL] [Abstract][Full Text] [Related]
8. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
10. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Griesenberg D; Nürnberg R; Bahlo M; Klapdor R Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197 [TBL] [Abstract][Full Text] [Related]
12. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Matsumoto K; Kinoshita T; Ishida T; Itoh H; Miki C; Suzuki H Surg Today; 1999; 29(1):91-2. PubMed ID: 9934841 [TBL] [Abstract][Full Text] [Related]
14. [Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (2)]. Ohkura H; Hattori N; Miyazaki I; Sawabu N; Tobe R; Kawai K; Abe O; Ishii M; Kawai T; Kamano T Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1907-12. PubMed ID: 2439021 [TBL] [Abstract][Full Text] [Related]
15. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568 [TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA]. Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399 [TBL] [Abstract][Full Text] [Related]
17. [Study on the clinical usefulness of NCC-ST-439 in breast cancer]. Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer. Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Carone MD; Aloe S; Tedesco M; Mancini R; Casale V; Carlini S; Casciani CU; Roselli M; Guadagni F Anticancer Res; 1999; 19(2B):1363-8. PubMed ID: 10365107 [TBL] [Abstract][Full Text] [Related]
19. [Significance of CEA and CA 19-9 for after care of curatively resected colorectal cancers]. Stapel A; Franke U; Putzki H Zentralbl Chir; 1992; 117(2):77-80. PubMed ID: 1315472 [TBL] [Abstract][Full Text] [Related]
20. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer]. Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]